161,95 €
161,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
81 °P sammeln
161,95 €
161,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
81 °P sammeln
Als Download kaufen
161,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
81 °P sammeln
Jetzt verschenken
161,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
81 °P sammeln
  • Format: PDF

After diabetic retinopathy, the varieties of retinal vein occlusion constitute the most prevalent category of retinal vascular disease. For macular edema associated with central retinal vein occlusion (CRVO), no effective therapy existed until 2009, despite decades of research and failed pilot therapies. This comprehensive, illustrated text integrates recent advances in treatments with the parallel progress in understanding of disease mechanisms. Complete with case studies, this text is perfect for retina specialists, ophthalmologists, optometrists, and residents and fellows in these fields.

  • Geräte: PC
  • ohne Kopierschutz
  • eBook Hilfe
  • Größe: 24.39MB
Produktbeschreibung
After diabetic retinopathy, the varieties of retinal vein occlusion constitute the most prevalent category of retinal vascular disease. For macular edema associated with central retinal vein occlusion (CRVO), no effective therapy existed until 2009, despite decades of research and failed pilot therapies. This comprehensive, illustrated text integrates recent advances in treatments with the parallel progress in understanding of disease mechanisms. Complete with case studies, this text is perfect for retina specialists, ophthalmologists, optometrists, and residents and fellows in these fields.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Dr. Browning is Retina Specialist at Charlotte Eye Ear Nose and Throat Associates in Charlotte, North Carolina, USA, and is involved with the Diabetic Retinopathy Clinical Research network.